130 related articles for article (PubMed ID: 38558988)
1. CB
Watkins J; Aradi P; Hahn R; Katona I; Mackie K; Makriyannis A; Hohmann AG
bioRxiv; 2024 Mar; ():. PubMed ID: 38558988
[TBL] [Abstract][Full Text] [Related]
2. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
3. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201.
AlKhelb D; Burke EL; Zvonok A; Iliopoulos-Tsoutsouvas C; Georgiadis MO; Jiang S; Ho TC; Nikas SP; Makriyannis A; Desai RI
Eur J Pharmacol; 2023 Dec; 960():176168. PubMed ID: 38059442
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
5. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.
Hruba L; Ginsburg BC; McMahon LR
J Pharmacol Exp Ther; 2012 Sep; 342(3):843-9. PubMed ID: 22718500
[TBL] [Abstract][Full Text] [Related]
6. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
7. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
[TBL] [Abstract][Full Text] [Related]
8. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Singh H; Schulze DR; McMahon LR
Psychopharmacology (Berl); 2011 Jun; 215(4):665-75. PubMed ID: 21246187
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of CB
Li X; Hempel BJ; Yang HJ; Han X; Bi GH; Gardner EL; Xi ZX
Eur Neuropsychopharmacol; 2021 Feb; 43():38-51. PubMed ID: 33334652
[TBL] [Abstract][Full Text] [Related]
10. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory action of exo- and endocannabinoids on [³H]GABA release are mediated by both CB₁and CB₂receptors in the mouse hippocampus.
Andó RD; Bíró J; Csölle C; Ledent C; Sperlágh B
Neurochem Int; 2012 Jan; 60(2):145-52. PubMed ID: 22133429
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
14. Absence of Entourage: Terpenoids Commonly Found in
Santiago M; Sachdev S; Arnold JC; McGregor IS; Connor M
Cannabis Cannabinoid Res; 2019; 4(3):165-176. PubMed ID: 31559333
[No Abstract] [Full Text] [Related]
15. Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.
Nguyen PT; Selley DE; Sim-Selley LJ
Neuroimage; 2010 Oct; 52(4):1243-51. PubMed ID: 20451624
[TBL] [Abstract][Full Text] [Related]
16. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
17. Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ
Henderson-Redmond AN; Sepulveda DE; Ferguson EL; Kline AM; Piscura MK; Morgan DJ
Psychopharmacology (Berl); 2022 May; 239(5):1289-1309. PubMed ID: 34165606
[TBL] [Abstract][Full Text] [Related]
18. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
19. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
20. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
